When a Half-Star Is Worth Hundreds of Millions

The Clover Health Ruling May Be Less About One Insurer—and More About a Growing Crisis of Confidence in Medicare Advantage Star Ratings

For years, Medicare Advantage organizations have treated CMS Star Ratings as one of the most consequential metrics in American healthcare. A half-star increase can unlock tens or even hundreds of millions of dollars in bonus payments. A half-star decrease can reduce rebates, weaken benefit offerings, and undermine a plan’s competitive position during enrollment season.

That is why a recent court victory by Clover Health has attracted attention far beyond a single insurer’s rating dispute.

In June 2026, CMS announced that it would recalculate 2026 Medicare Advantage Star Ratings after losing a federal court challenge brought by Clover Health. The agency’s decision affects not only Clover but potentially dozens of Medicare Advantage contracts across the industry.  The immediate story is straightforward: Clover won. The more important story is what the case reveals about the growing tension between regulatory methodology, judicial oversight, and the financial architecture of Medicare Advantage.

The Dispute Was Never Really About Half a Star

At the center of the case was Clover’s claim that CMS improperly calculated its 2026 Star Rating. The insurer argued that certain measures included in the rating methodology exceeded the agency’s statutory authority and were implemented without the procedural safeguards required under federal law. A federal judge in Georgia agreed with significant portions of that argument and ordered CMS to recalculate Clover’s rating.

The financial stakes were substantial. According to court filings and industry analyses, Clover argued that the reduction from 4 stars to 3.5 stars jeopardized approximately $120 million in quality bonus payments and related revenue tied to its Medicare Advantage business.

After CMS recalculated the ratings, Clover’s score reportedly increased from 3.5 stars to 4.5 stars—a dramatic shift for a program in which even a half-star movement can materially alter financial performance.

The size of that adjustment raises an uncomfortable question: If a court can determine that a methodology was flawed enough to move a contract by an entire star, how much confidence should policymakers place in the precision of the Star Ratings system itself?

A Problem CMS Has Encountered Before

The Clover case did not emerge in isolation. Over the past several years, Medicare Advantage organizations have increasingly turned to litigation when challenging CMS ratings decisions.

UnitedHealth, Elevance Health, SCAN, Humana, and Centene have all pursued legal action over various aspects of the Star Ratings methodology. Several have successfully obtained recalculations that improved their ratings and restored significant bonus revenue.

Historically, these disputes were often viewed as narrow disagreements over specific measures or technical scoring decisions.

The Clover litigation feels different. Rather than challenging a particular audit result or operational metric, the case questioned whether CMS had legal authority to use certain measures in the first place and whether the agency followed proper rulemaking procedures when implementing them.

That distinction matters because it shifts the debate from measurement accuracy to regulatory legitimacy.

The Star Ratings Paradox

The controversy highlights a paradox that has existed within Medicare Advantage for years. The Star Ratings program was designed to help beneficiaries identify higher-quality plans while rewarding insurers that deliver better outcomes.

In theory, it aligns incentives around quality. In practice, it has evolved into one of the largest financial redistribution mechanisms in the Medicare Advantage ecosystem.

Plans that achieve four stars or higher gain access to quality bonus payments and enhanced rebates. Those additional dollars frequently translate into richer supplemental benefits, lower premiums, and stronger market positioning. Plans that fall below key thresholds lose those advantages.

As a result, Star Ratings increasingly influence insurer revenue, enrollment growth, benefit design, and investor expectations. The ratings system was originally intended to measure quality. Today, it also determines winners and losers in a market covering more than half of all Medicare beneficiaries. That transformation has inevitably increased legal scrutiny.

What the Court May Have Exposed

The Clover ruling exposes a vulnerability that extends beyond a single insurer. For years, industry critics have argued that portions of the Star Ratings framework rely on measures that are only indirectly connected to clinical quality or patient outcomes.

Others have questioned whether increasingly complex methodologies produce ratings that beneficiaries can easily interpret. The court did not invalidate the entire program. However, it did suggest that certain components of the methodology may have exceeded statutory boundaries or lacked appropriate procedural support.

That finding creates uncertainty for CMS. If other insurers identify similar legal vulnerabilities within the ratings framework, additional challenges could follow. Indeed, some healthcare attorneys and policy analysts already view the decision as a potential roadmap for future litigation.

Why This Matters Beyond Insurers

Most discussions of Star Ratings focus on health plans because they receive the financial consequences. But beneficiaries may ultimately feel the effects as well. Every recalculation changes competitive dynamics within Medicare Advantage.

Plans that receive higher ratings gain access to additional funding that can support supplemental benefits such as dental coverage, vision services, transportation programs, and reduced cost-sharing. Conversely, plans that lose ratings often face pressure to reduce benefits, raise premiums, or absorb margin compression.

When litigation repeatedly alters ratings after they have already been published, questions emerge about whether beneficiaries are making enrollment decisions based on information that could later change.

That is not merely an administrative concern. It affects one of the primary quality signals available to Medicare consumers.

The Deeper Policy Question

The larger issue raised by the Clover decision is whether Medicare Advantage has outgrown the Star Ratings framework that was originally designed to evaluate it. When the program was smaller, quality measurement and bonus payments were relatively limited policy tools.

Today, Medicare Advantage has become a central pillar of Medicare itself, with enormous financial implications for insurers, providers, investors, and beneficiaries. Under those circumstances, every methodological choice becomes consequential. Every measure becomes litigable. Every half-star becomes economically significant.

The Clover case demonstrates that courts are increasingly willing to examine not only how CMS applies the methodology but whether aspects of the methodology are legally defensible. That shift could fundamentally alter the relationship between regulators and Medicare Advantage organizations.

***

CMS has emphasized that the recalculation is limited and does not automatically create windfalls across the industry. Yet the agency’s decision to revisit ratings following the court ruling reinforces a broader reality: Star Ratings are no longer merely a quality measurement program. They have become a high-stakes regulatory instrument whose financial consequences rival many traditional reimbursement policies.

For Medicare Advantage organizations, the lesson is clear. Future performance may depend not only on quality improvement initiatives but also on how successfully plans navigate increasingly complex regulatory and legal challenges.

For CMS, the challenge is more difficult. The agency must preserve the credibility of a ratings system that influences billions of dollars in payments while simultaneously defending the legal foundations upon which that system rests. The Clover litigation suggests those foundations may face greater scrutiny than ever before.

Sources

1. Healthcare Dive. CMS recalculates Medicare Advantage stars after Clover lawsuit loss. June 2026.
2. Becker’s Payer Issues. Clover beats CMS in Medicare Advantage star ratings lawsuit. May 2026.
3. STAT News. CMS reworks Medicare Advantage star ratings after legal action. June 2026.
4. Mintz. Clover Health Decision Raises Significant Questions for CMS Star Ratings Methodology. June 2026.
5. Crowell & Moring. Clover Insurance v. HHS: Court Holds 20 Star Ratings Measures Unlawful. May 2026.
6. Healthcare Finance News. CMS voluntarily recalculating 2027 MA star ratings bonus payments. June 2026.
7. Healthcare Dive. CMS recalculates Medicare Advantage stars for UnitedHealth and Centene. December 2024.
8. Reuters. CMS to rework quality ratings for Medicare Advantage plans. June 2024.